ArticleBMC infectious diseases2026
Uncovering the impact of co-infections on disease severity and mortality in pulmonary cryptococcosis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundIncreasing case reports and monocentric studies suggest that co-infections may be associated with poorer outcomes in patients with pulmonary cryptococcosis (PC), including both people living with HIV (PLWH) and HIV-negative individuals. However, systematic cohort-based evidence evaluating the prognostic impact of co-infections remains limited.
methodsTotal of 454 patients with PC (239 PLWH and 215 non-HIV) were included to compare clinical characteristics, CT imaging features, and relevant prognostic factors according to their co-infection status.
resultsAmong non-HIV patients, co-infections were linked to older age (53.42 vs. 45.46 years, p = 0.02), while no age difference was observed among PLWH. No HIV-negative patient had multiple co-infections, and all 1-year deaths occurred in those with bacterial co-infection; in contrast, 20% of PLWH had dual co-infections, most commonly tuberculosis. PLWH more frequently presented with fever and central nervous system symptoms, and co-infected PLWH had greater disease severity, reflected by higher SOFA, CURB-65, and APACHE II scores. Among co-infected patients, disease severity and 52-week median survival were comparable across HIV and dissemination status, although non-HIV patients experienced a markedly longer diagnostic delay [13.5 vs. 2.0 days; p < 0.0001]. Over 52 weeks, Pneumocystis jirovecii pneumonia (PCP), identified only in PLWH, was independently associated with mortality (HR = 3.81; p = 0.002), whereas bacterial co-infection showed a non-significant increase in mortality risk (HR = 1.51; p = 0.44). In the overall cohort, a high-risk APACHE II score was associated with more than a 15-fold increase in mortality, while nodular-plus-patchy CT lesions were associated with a greater than fivefold increase. PLWH had an 11.3-fold higher mortality risk than non-HIV patients, with SOFA score ≥ 2, high-risk APACHE II score, and absence of standard antifungal therapy further associated with poorer survival.
conclusionCo-infection patterns differed by HIV status: multiple and diverse co-infections were common in PLWH, whereas bacterial co-infections predominated in non-HIV patients. Among co-infected patients, survival was comparable regardless of HIV status or extrapulmonary dissemination. Earlier recognition and timely diagnosis may improve the clinical management of pulmonary cryptococcosis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.